Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et klinisk forsøg med BAT4406F-injektion hos patienter med neuromyelitis opticaspektrumforstyrrelser

29. september 2026 opdateret af: Bio-Thera Solutions

Et fase II/III-studie for at evaluere effektiviteten og sikkerheden af ​​BAT4406F-injektion hos patienter med neuromyelitis Optica Lineage-sygdom

This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .

Studieoversigt

Status

Aktiv, ikke rekrutterende

Detaljeret beskrivelse

This study was a phase II/III multicenter, randomized, double-blind, placebo-controlled study, which was divided into screening period (4 weeks) , randomized control period (RCP) , and open-label period (Olp)A total of 162 subjects were enrolled during the screening period and randomly assigned 2:1 to either the BAT4406F group or the placebo group after randomization on Day 1 of the RCP, subjects would receive BAT4406F (at a dose of 500mg) or placebo, intravenously, at D 1 and D 182, respectively.

If any of the following conditions occur, subjects can enter OLP from RCP: 1. Subjects who complete the 52-week RCP study without recurrence of NMOSD can enter Olp within 14 days after the end of the RCP study. 2. In the stage of RCP, NMOSD recurred. After rescue therapy, the patients with stable condition could enter OLP within 28 days after diagnosis. Subjects continued to participate in the RCP study if they were not identified by CEC as having a relapse upon examination. 3. When a protocol-defined first relapse event of 35 cases is observed, or when all 162 subjects have completed randomization and 12 months have elapsed since the first dose in the last of these subjects, or when recommended by the Independent Data Monitoring Committee (IDMC) , the RCP study should be stopped for enrolled subjects, and all enrolled subjects at the RCP stage should stop the RCP study within 14 days of entry into OLP, after which subjects will receive BAT4406F injection at the same dose as RCP, at d 1 of OLP. After termination of the RCP study with BAT4406F every 6 months, subjects were given the option of enrolling in the OLP study.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

162

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Baotou, Kina
        • The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
      • Beijing, Kina
        • Beijing Hospital
      • Beijing, Kina
        • China-japan friendship Hospital
      • Beijing, Kina
        • The first hospital of Peking University
      • Changsha, Kina
        • The Central South University Xiang Ya Hospital
      • Changsha, Kina
        • Xiangya 2nd hospital of central south university
      • Chongqing, Kina
        • First affiliated hospital of chongqing medical university
      • Dalian, Kina
        • The first affiliated hospital of Dalian Medical University
      • Fuzhou, Kina
        • First affiliated hospital of fujian medical university
      • Guangzhou, Kina
        • The first hospital affiliated to sun yat-sen university
      • Guangzhou, Kina
        • The third hospital affiliated to sun yat-sen university
      • Guangzhou, Kina
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      • Guangzhou, Kina
        • The first People's Hospital of Guangzhou
      • Hangzhou, Kina
        • People's Hospital of Zhejiang province
      • Hefei, Kina
        • Anhui Provincial Hospital
      • Hefei, Kina
        • Second Affiliated Hospital of Anhui Medical University
      • Jinan, Kina
        • Shandong University Qilu Hospital
      • Jingzhou, Kina
        • Jingzhou Central Hospital
      • Kunming, Kina
        • First Affiliated Hospital of the Kunming Medical University
      • Nanchang, Kina
        • Second Affiliated Hospital of Nanchang University
      • Nanchong, Kina
        • Affiliated Hospital of North Sichuan Medical College
      • Nanjing, Kina
        • Drum Tower Hospital affiliated to Medical College of Nanjing University
      • Nanjing, Kina
        • The Chinese people's liberation army general hospital in eastern theater
      • Nanjing, Kina
        • Southeast university affiliated zhongda hospital
      • Nantong, Kina
        • The first People's Hospital of Nantong
      • Qingdao, Kina
        • Qingdao municipal hospital
      • Shanghai, Kina
        • Mount Hua Hospital affiliated to Fudan University
      • Shanghai, Kina
        • Shuguang hospital affiliated to Shanghai University of Traditional Chinese medicine
      • Shanghai, Kina
        • Zhongshan hospital affiliated to Fudan University
      • Shenzhen, Kina
        • Shenzhen city people's hospital
      • Shijia Zhuang, Kina
        • Second Hebei Medical University Hospital
      • Shijiazhuang, Kina
        • The Third Hospital of Hebei Medical University
      • Suzhou, Kina
        • The Second Affiliated Hospital of Suzhou University
      • Suzhou, Kina
        • First Affiliated Hospital of Suzhou University
      • Taiyuan, Kina
        • The first hospital of shanxi medical university
      • Tianjin, Kina
        • Tianjin Medical University General Hospital
      • Wenzhou, Kina
        • The first hospital affiliated to wenzhou medical college
      • Wuhan, Kina
        • Tongji hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuhan, Kina
        • Xiehe hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuxi, Kina
        • Wuxi city people's hospital
      • Xi'an, Kina
        • Second Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
      • Xi'an, Kina
        • Xi'an high-tech Hospital Co. , Ltd.
      • Xianyang, Kina
        • Yan 'an University Xianyang Hospital Co. , Ltd.
      • Zhengzhou, Kina
        • Henan province people's hospital
      • Zhenzhou, Kina
        • Zhengzhou university first affiliated hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age greater than or equal to the age of 18 and less than or equal to 65 patients, gender not limited;
  2. Met the 2015 international NMO diagnostic panel (IPND) criteria for NMOSD, And AQP4-IGG positive patients
  3. Screening before 2 times at least 2 years experience with clinical records of relapse,or experienced at least 1 clinically documented recurrence within 1 year prior to screening
  4. For subjects who had a relapse before screening, symptoms needed to be stable for at least 4 weeks before randomization
  5. Into the group of former dosage of corticosteroids under 30 mg and prednisone equivalent,and the trial drug must be used within a month after the withdrawal of hormones
  6. The score of EDSS 7 or less
  7. Has the fertility of men and women must agree during treatment and 6 months after the last dose of using effective birth control method;
  8. Agreed to participate in trials, and books to sign the informed consent

Exclusion Criteria:

  1. CD19 + b-cell count below the lower limit of normal, b-cell-scavenger drugs used 6 months before baseline or within 5 half-lives of the drug, whichever is older (including but not limited to Rituximab, enalizumab, etc.) ;

  2. 6 months prior to the baseline used other monoclonal antibody therapy;Baseline used within five half-life before other biological preparation;

  3. Used it for 3 months prior to the baseline McCaw phenol ester, azathioprine and methotrexate;6 months prior to the baseline using cyclophosphamide;Baseline before five half-life

  4. Within a month before the filter used intravenous immunoglobulin (IVIG), plasma exchange (PE);

  5. Within 4 weeks before screening received vaccine or live attenuated;Within 2 weeks before the baseline received inactivated vaccine;Baseline received within 4 weeks before the new coronavirus vaccine

  6. In another clinical study and the baseline from the test drug treatment under three months or 5 half-life of the drug (the long time limit shall prevail);

  7. This test for monoclonal antibody has a history of allergies, known in drug allergy patients;Serious drug allergy or for two or over two kinds of food or drugs;

  8. 6 months prior to screening, except NMOSD need continuous oral or intravenous glucocorticoid dose > 20 mg/day of any more than 21 days

  9. Abnormal liver, kidney and bone marrow reserve

  10. HIV positive at HIV history or enrollment screening; History of hepatitis B Andor hepatitis C or Hepatitis B surface antigen (HBSAG) positivity at screening [ or Hepatitis B core antibody positive, hepatitis B surface antibody negative, Hepatitis B virus deoxynucleotides (HBV DNA) quantification exceeding normal range ] ; Or Hepatitis C virus (HCV) antibody positive [ with HCV-rna quantitation exceeding the normal range ] , Treponema pallidum antibody positive at the time of enrollment;

  11. Comply with any of the following subjects a latent or active TB infection related standards:

    1. Current or past people with active TB;
    2. In history and/or physical examination during filter tip physical signs or symptoms of active TB;
    3. Recent close contact with people with active TB;
    4. At the time of screening, the positive result of TB infected T cells was found. A test could be repeated if the subject's first tb-infected t-cell test result was inconclusive, and the patient was excluded from this study if the test result was inconclusive (or positive) again.
  12. Covid-19 infection was diagnosed with clinical symptoms or signs consistent with 2019 coronavirus (COVID-19) infection (eg, fever, dry cough, dyspnea, sore throat, and fatigue) within 4 weeks before screening or during screening, or upon appropriate laboratory testing (at the discretion of the investigator or in accordance with local regulations) . If COVID-19 infection is confirmed before screening, appropriate laboratory testing is required to confirm that the infection has been cured;

  13. Suffering from metabolic, hematological, renal, hepatic, pulmonary, neuroendocrine, cardiac, infectious, gastrointestinal or other autoimmune diseases, the researchers believe there is an unacceptable risk to patients, or it may affect NMOSD assessment;

  14. According to the researchers, there was a history of drug and alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 125 mL of wine) in the 12 months before screening;

  15. Subjects who are unable to undergo an MRI scan (for example, are allergic to Gd-containing MRI contrast media, have a pacemaker, defibrillator, or other metallic object with internal or external limitations to performing an MRI scan) ;

  16. Pregnant or lactating women, and screening or baseline pregnancy test positive female subjects;

  17. Researchers think that the other does not fit to participate in this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental group:BAT4406F

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

Aktiv komparator: Control group:BAT4406F Placebos

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacodynamics
Tidsramme: RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years

The follow-up time point of peripheral blood before and after the analysis to the medicine CD19 + B lymphocytes proportion/count change

RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years
Pharmacodynamics
Tidsramme: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

Serum immunoglobulin (IgG and IgM) levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacodynamics
Tidsramme: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

AQP4-IgG levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacokinetics(PK)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Tmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmin

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

AUC0-tau

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

t1/2

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

CL

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Vd

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Immunogenicity evaluation
Tidsramme: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Resistant antibody positive rate (ADA)

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years
Immunogenicity evaluation
Tidsramme: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

The titers of Ada positive samples

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Vital signs
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal vital signs

Through study completion,up to 49 months. And OLP maximum period for 3 years.
physical examination
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal physical examination findings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Laboratory tests
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal laboratory test results

Through study completion,up to 49 months. And OLP maximum period for 3 years.
electrocardiogram( ECG )
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal ECG readings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Adverse events(AE)
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Adverse events (AE) is happening, is happening because of adverse events leading to withdrawal Adverse events associated with drugs The occurrence of Serious adverse events (SAE)

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Injection site reactions
Tidsramme: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with injection site reactions

Through study completion,up to 49 months. And OLP maximum period for 3 years.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Xiangjun Chen, Doctor, Huashan Hospital
  • Ledende efterforsker: Chunfeng Liu, Doctor, Second Affiliated Hospital of Suzhou University
  • Ledende efterforsker: Qun Xue, Doctor, First Affiliated Hospital of Suzhou University
  • Ledende efterforsker: Yan Jiang, Doctor, Anhui Provincial Hospital
  • Ledende efterforsker: Yuying Zhao, Doctor, Shandong University Qilu Hospital
  • Ledende efterforsker: Li Guo, Doctor, Second Hebei Medical University Hospital
  • Ledende efterforsker: Meini Zhang, Doctor, The First Affiliated Hospital of Shanxi Medical University
  • Ledende efterforsker: Huan Yang, Doctor, The Central South University Xiang Ya Hospital
  • Ledende efterforsker: Daishi Tian, Doctor, Tongji hospital affiliated to Tongji Medical College
  • Ledende efterforsker: Yuming Xu, Doctor, The First Affiliated Hospital of Zhengzhou University
  • Ledende efterforsker: Jianglong Tu, Doctor, Second Affiliated Hospital of Nanchang University
  • Ledende efterforsker: Wei Qiu, Doctor, The third hospital affiliated to sun yat-sen university
  • Ledende efterforsker: Honghao Wang, Doctor, The First People's Hospital of Guangzhou
  • Ledende efterforsker: Xiaoling Luo, Doctor, Shenzhen city people's hospital
  • Ledende efterforsker: Aiyu Lin, Doctor, First Affiliated Hospital of Fujian Medical University
  • Ledende efterforsker: Chunming Xie, Doctor, China University Hospital of Southeast University
  • Ledende efterforsker: Xiang Li, Doctor, The first hospital affiliated to wenzhou medical college
  • Ledende efterforsker: Lan Tan, Doctor, Qingdao City Hospital
  • Ledende efterforsker: Fudong Shi, Doctor, Tianjin Medical University General Hospital
  • Ledende efterforsker: Jiewen Zhang, Doctor, Henan Provincial People's Hospital
  • Ledende efterforsker: Jing Ding, Doctor, Shanghai Zhongshan Hospital
  • Ledende efterforsker: Ping Chen, Doctor, Xianyang yanan university hospital co., LTD
  • Ledende efterforsker: Zunbo Li, Doctor, Xi'an high-tech Hospital Co. , Ltd.
  • Ledende efterforsker: Qihe Dai, Doctor, Jingzhou city central hospital
  • Ledende efterforsker: Dan Liu, Doctor, the first hospital of Baotou medicine college
  • Ledende efterforsker: Junyan Liu, Doctor, Hebei Medical University Third Hospital
  • Ledende efterforsker: Yiqi Wang, Doctor, Zhejiang Province People's Hospital
  • Ledende efterforsker: Bo Hu, Doctor, Xiehe hospital affiliated to tongji medical college
  • Ledende efterforsker: Yanbing Han, Doctor, First Affiliated Hospital of the Kunming Medical University
  • Ledende efterforsker: Feng Wang, Doctor, Wuxi city people's hospital
  • Ledende efterforsker: Zhanhua Liang, Doctor, The First Affiliated Hospital of Dalian Medical University
  • Ledende efterforsker: Weihe Zhang, Doctor, Sino-Japanese Friendship Hospital
  • Ledende efterforsker: Xiangyang Zhu, Doctor, Nantong First People's Hospital
  • Ledende efterforsker: Xinfeng Liu, Doctor, The Chinese people's liberation army general hospital in eastern theater
  • Ledende efterforsker: Weidong Pan, Doctor, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  • Ledende efterforsker: Wei Lu, Doctor, The Central South University Xiang YA II hospital
  • Ledende efterforsker: Huiyu Feng, Doctor, The first hospital affiliated to sun yat-sen university
  • Ledende efterforsker: Yamei Tang, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Ledende efterforsker: Juming Yu, Doctor, Affiliated Hospital of North Sichuan Medical College
  • Ledende efterforsker: Jun Guo, Doctor, The Second Affiliated Hospital of the PLA Air Force Military Medical University
  • Ledende efterforsker: Yanghua Tian, Doctor, The Second Hospital of Anhui Medical University
  • Ledende efterforsker: Feng Gao, Doctor, The first hospital of Peking University
  • Ledende efterforsker: Yun Xu, Doctor, Drum tower hospital affiliated to nanjing university school of medicine

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. august 2023

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

31. juli 2023

Først indsendt, der opfyldte QC-kriterier

12. september 2023

Først opslået (Faktiske)

21. september 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • BAT-4406F-002-CR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner